Price
CHART BY
Frequently asked questions
What is Kymera Therapeut's market capitalization?
What is the Earnings Per Share (EPS) for Kymera Therapeut?
What are the analyst ratings and target price for Kymera Therapeut's stock?
What is Kymera Therapeut's revenue over the trailing twelve months?
What is the EBITDA for Kymera Therapeut?
What is the free cash flow of Kymera Therapeut?
How many employees does Kymera Therapeut have, and what sector and industry does it belong to?
What is the free float of Kymera Therapeut's shares?
Financials
- Market Cap
- $9.79B
- EPS (TTM)
- -$3.242
- Free Float
- 74.59M
- Revenue (TTM)
- $105.00M
- EBITDA (TTM)
- -$338.09M
- Free Cashflow (TTM)
- -$237.96M
Pricing
- 52W span
- $47.91$129.80
Analyst Ratings
The price target is $137.73 and the stock is covered by 23 analysts.
Buy
21
Hold
2
Sell
0
Information
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of human diseases through the development of innovative, highly differentiated medicines. It focuses on discovering and developing novel small-molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s natural protein degradation system. The company leverages targeted protein degradation (TPD) to develop medicines that address critical health challenges and have the potential to significantly improve patients lives. Its pipeline emphasizes oral small-molecule degraders, offering a new generation of convenient and highly effective therapies. The company was founded by Bruce Lee Booth and Nello Mainolfi on September 29, 2015 and is headquartered in Watertown, MA.
- Employees
- 238
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- KYMR